Concentrated ascites re-infusion therapy for pseudo-Meigs' syndrome complicated by massive ascites in large pedunculated uterine leiomyoma.

Pseudo-Meigs' syndrome accompanied by massive ascites in uterine leiomyoma is rare. We encountered a rare case of a 37-year-old, nulliparous woman with a lower abdominal tumor and severe abdominal distention due to massive ascites. Serum cancer antigen 125 and vascular endothelial growth factor levels were elevated to 1007.

Relative contribution of weight-bearing and non-weight-bearing effect of adipose tissue to bone mineral density in postmenopausal women.

Aim:   To investigate the relative contributions of weight-bearing and non-weight-bearing effects of adipose tissue to bone mineral density (BMD) in postmenopausal women.

Material And Methods:   The subjects were 228 postmenopausal women aged 50-75 years. Age, years since menopause (YSM), height, body weight, and body mass index were recorded.

Difference in non-weight-bearing effects on bone mineral density between trunk and peripheral fat mass in women with polycystic ovary syndrome.

Aim: To investigate the difference in non-weight-bearing effects on bone mineral density (BMD) between trunk and peripheral fat mass in women with polycystic ovary syndrome (PCOS).

Methods: Subjects were 123 amenorrheic PCOS women with right side dominance. Age, height, body weight, and body mass index were recorded.

Non-weight-bearing effect of trunk and peripheral fat mass on bone mineral density in pre- and post-menopausal women.

Objective: To investigate the non-weight-bearing effect of trunk fat mass (composed of visceral and subcutaneous fat mass) and peripheral fat mass (subcutaneous fat mass alone) on bone mineral density (BMD) in pre- and post-menopausal women.

Methods: The subjects were 412 pre-menopausal women, 20-50 years of age and 228 post-menopausal women, 50-75 years of age. Age, years since menopause (YSM), height, body weight, and body mass index were recorded.

Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.

Aim: To investigate aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.

Methods: Subjects were 17 postmenopausal breast cancer patients (mean age, 63.3 +/- 9.

Difference in segmental lean and fat mass components between pre- and postmenopausal women.

Objective: To investigate the differences in segmental body composition (lean and fat mass components) between pre- and postmenopausal women.

Design: Participants were 413 premenopausal women aged 20 to 53 years old and 229 postmenopausal women aged 50 to 75 years old with right-side dominance. Age, height, weight, body mass index, age at menopause, and years since menopause were recorded.

Bone mineral density in breast cancer patients with positive estrogen receptor tumor status.

Aim: The aim was to investigate bone mineral density (BMD) in breast cancer patients with positive estrogen receptor (ER) tumor status.

Methods: The participants were 110 postmenopausal breast cancer patients with positive estrogen receptor (ER+) tumor status. Two hundred and sixty-one age-matched, healthy postmenopausal women, all of whom were selected from our pooled data, served as controls.